KNSA — Kiniksa Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $1.27bn
- $1.06bn
- $270.26m
- 76
- 13
- 90
- 62
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 226.22 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -7.71% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.89 | ||
| Price to Tang. Book | 3.01 | ||
| Price to Free Cashflow | 96.3 | ||
| Price to Sales | 4.2 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -6.6% | ||
| Return on Equity | 2.09% | ||
| Operating Margin | -10.12% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 38.54 | 220.18 | 270.26 | 382.61 | 519.14 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | -92.48 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Company’s ARCALYST is interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Company’s Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα).
Directors
- Sanjiv Patel CHM (51)
- Mark Ragosa CFO (47)
- Eben Tessari COO (40)
- John Paolini SVP (56)
- Madelyn Zeylikman VPR
- Ross Moat VPR (40)
- Felix Baker LED (52)
- Stephen Biggar IND (50)
- G. Bradley Cole IND (65)
- Richard Levy IND (63)
- Thomas Malley IND (52)
- Tracey McCain IND (53)
- Kimberly Popovits IND (62)
- Barry Quart IND (64)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- July 21st, 2015
- Public Since
- May 24th, 2018
- No. of Shareholders
- 15
- No. of Employees
- 297
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 70,940,145
- Address
- Clarendon House, 2 Church Street, HAMILTON, HM11
- Web
- https://www.kiniksa.com/
- Phone
- +1 4417814399100
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for KNSA
Kiniksa Pharmaceuticals Ltd Annual Shareholders Meeting
Q2 2024 Kiniksa Pharmaceuticals Ltd Earnings Release
Similar to KNSA
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Kiniksa Pharmaceuticals share price?
As of Today at 19:12 UTC, shares in Kiniksa Pharmaceuticals are trading at $17.88. This share price information is delayed by 15 minutes.
How has the Kiniksa Pharmaceuticals share price performed this year?
Shares in Kiniksa Pharmaceuticals last closed at $17.88 and the price had moved by +66.17% over the past 365 days. In terms of relative price strength the Kiniksa Pharmaceuticals share price has outperformed the S&P500 Index by +35.85% over the past year.
What are the analyst and broker recommendations for Kiniksa Pharmaceuticals?
The overall consensus recommendation for Kiniksa Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Kiniksa Pharmaceuticals dividend yield?
Kiniksa Pharmaceuticals does not currently pay a dividend.
Does Kiniksa Pharmaceuticals pay a dividend?
Kiniksa Pharmaceuticals does not currently pay a dividend.
When does Kiniksa Pharmaceuticals next pay dividends?
Kiniksa Pharmaceuticals does not currently pay a dividend.
How do I buy Kiniksa Pharmaceuticals shares?
To buy shares in Kiniksa Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Kiniksa Pharmaceuticals?
As of the previous close price of $17.88, shares in Kiniksa Pharmaceuticals had a market capitalisation of $1.27bn.
Where are Kiniksa Pharmaceuticals shares listed?
Here are the trading details for Kiniksa Pharmaceuticals:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: KNSA
What kind of share is Kiniksa Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Kiniksa Pharmaceuticals is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Kiniksa Pharmaceuticals share price forecast for 2024?
The analyst consensus target price for shares in Kiniksa Pharmaceuticals is $30.00. That is 67.79% above the last closing price of $17.88.
Analysts covering Kiniksa Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$0.15 for the next financial year.
What is the trend in the Kiniksa Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Kiniksa Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -4.21%.
As of the last closing price of $17.88, shares in Kiniksa Pharmaceuticals were trading +0.87% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Kiniksa Pharmaceuticals PE Ratio?
The Kiniksa Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 226.22. The shares last closed at $17.88.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals' management team is headed by:
- Sanjiv Patel - CHM
- Mark Ragosa - CFO
- Eben Tessari - COO
- John Paolini - SVP
- Madelyn Zeylikman - VPR
- Ross Moat - VPR
- Felix Baker - LED
- Stephen Biggar - IND
- G. Bradley Cole - IND
- Richard Levy - IND
- Thomas Malley - IND
- Tracey McCain - IND
- Kimberly Popovits - IND
- Barry Quart - IND